BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ, Dominika NADASKA and Ivan MALIK. Research in the Field of Drug Design and Development. Pharmaceuticals. BASEL: MDPI, 2023, vol. 16, No 9, p. 1-23. ISSN 1424-8247. Available from: https://dx.doi.org/10.3390/ph16091283.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Research in the Field of Drug Design and Development
Authors BIALA, Grazyna (guarantor), Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ (203 Czech Republic, belonging to the institution), Dominika NADASKA and Ivan MALIK.
Edition Pharmaceuticals, BASEL, MDPI, 2023, 1424-8247.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.600 in 2022
RIV identification code RIV/00216224:14160/23:00132055
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.3390/ph16091283
UT WoS 001074283700001
Keywords in English drug discovery; drug synthesis; in vivo studies; in vitro studies; clinical trials
Tags rivok, ÚChL
Tags International impact, Reviewed
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 27/10/2023 15:29.
Abstract
The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5-10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society's insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrad group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.
PrintDisplayed: 17/7/2024 09:34